BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HB0017 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HB0017\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07920861-1806@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HB0017: Phase 1 readout est. (NCT07920861)
DESCRIPTION:HB0017\, phase 1\, Psoriasis.\nStudy: A Study of HB0017 Injecti
 on in Healthy Volunteers to Evaluate Safety and Tolerability of a Single S
 ubcutaneous Injection in Low-Body-Weight Subjects\; and Pharmacokinetics a
 t Different Subcutaneous Injection Sites at the Same Dose\nEstimated prima
 ry completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/hb0017#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07920861
URL:https://assetmemo.bio/drug/hb0017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
